13771
2012
eng
2012
article
1
2016-08-25
--
--
The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis
Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86 ) or no adjuvant ADT (group 2, n=86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.
Advances in Urology
10.1155/2012/612707
urn:nbn:de:bvb:20-opus-137712
Advances in Urology Volume 2012 (2012), Article ID 612707, 6 pages. DOI: 10.1155/2012/612707
Maria Schubert
Steven Joniau
Paolo Gontero
Susanne Kneitz
Claus-Jürgen Scholz
Burkhard Kneitz
Alberto Briganti
R. Jeffery Karnes
Bertrand Tombal
Jochen Walz
Chao-Yu Hsu
Giansilvio Marchioro
Pia Bader
Chris Bangma
Detlef Frohneberg
Markus Graefen
Fritz Schröder
Paul van Cangh
Hein van Poppel
Martin Spahn
eng
uncontrolled
prostate cancer
eng
uncontrolled
adjuvant hormonal treatment
Chirurgie und verwandte medizinische Fachrichtungen
open_access
Urologische Klinik und Poliklinik
Förderzeitraum 2011
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/13771/Schubert_Advances_Urology_612707.pdf
9682
2013
eng
article
1
--
--
--
Distinct microRNA Expression Profile in Prostate Cancer Patients with Early Clinical Failure and the Impact of let-7 as Prognostic Marker in High-Risk Prostate Cancer
Background
The identification of additional prognostic markers to improve risk stratification and to avoid overtreatment is one of the most urgent clinical needs in prostate cancer (PCa). MicroRNAs, being important regulators of gene expression, are promising biomarkers in various cancer entities, though the impact as prognostic predictors in PCa is poorly understood. The aim of this study was to identify specific miRNAs as potential prognostic markers in high-risk PCa and to validate their clinical impact.
Methodology and Principal Findings
We performed miRNA-microarray analysis in a high-risk PCa study group selected by their clinical outcome (clinical progression free survival (CPFS) vs. clinical failure (CF)). We identified seven candidate miRNAs (let-7a/b/c, miR-515-3p/5p, -181b, -146b, and -361) that showed differential expression between both groups. Further qRT-PCR analysis revealed down-regulation of members of the let-7 family in the majority of a large, well-characterized high-risk PCa cohort (n = 98). Expression of let-7a/b/and -c was correlated to clinical outcome parameters of this group. While let-7a showed no association or correlation with clinical relevant data, let-7b and let-7c were associated with CF in PCa patients and functioned partially as independent prognostic marker. Validation of the data using an independent high-risk study cohort revealed that let-7b, but not let-7c, has impact as an independent prognostic marker for BCR and CF. Furthermore, we identified HMGA1, a non-histone protein, as a new target of let-7b and found correlation of let-7b down-regulation with HMGA1 over-expression in primary PCa samples.
Conclusion
Our findings define a distinct miRNA expression profile in PCa cases with early CF and identified let-7b as prognostic biomarker in high-risk PCa. This study highlights the importance of let-7b as tumor suppressor miRNA in high-risk PCa and presents a basis to improve individual therapy for high-risk PCa patients.
PLoS ONE
10.1371/journal.pone.0065064
urn:nbn:de:bvb:20-opus-96825
In: PLoS ONE (2013) 8: 6, doi:10.1371/journal.pone.0065064
Maria Schubert
Martin Spahn
Susanne Kneitz
Claus Jürgen Scholz
Steven Joniau
Philipp Stroebel
Hubertus Riedmiller
Burkhard Kneitz
eng
uncontrolled
biomarkers
eng
uncontrolled
gene expression
eng
uncontrolled
gene targeting
eng
uncontrolled
luciferase
eng
uncontrolled
MircoRNA
eng
uncontrolled
microarrays
eng
uncontrolled
oncogenes
eng
uncontrolled
prostate cancer
Medizin und Gesundheit
open_access
Urologische Klinik und Poliklinik
Theodor-Boveri-Institut für Biowissenschaften
Förderzeitraum 2013
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/9682/Schubert_journal.pone.0065064.pdf